As she awaited a heart ablation to treat her AFib, Dolores Catania turned to food for comfort. After her procedure, she ...

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

As Miami-based Veru continues development of its enobosarm to prevent muscle wasting in patients being treated for obesity, ...

The late-stage readout suggests that HRS9531 can hold its own against Eli Lilly’s blockbuster GLP-1/GIP agonist Zepbound, ...

In this population-based cohort study, patients with type 2 diabetes who received glucagon-like peptide-1 receptor agonists had a higher risk of developing gastroesophageal reflux disease and ...

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

Treating nicotine addiction with glucagon-like peptide 1 receptor agonists is associated with less weight gain compared with other smoking cessation treatments.

GLP-1 agonists may help reduce acetazolamide dosage in patients with idiopathic intracranial hypertension without changing clinical outcome.

Doctors explain the research behind taking a GLP-1 for PCOS treatment and why these drugs may bring relief from hormonal symptoms in some people.